MedTrace Logo

Randomized Trial of Aspirin and Cataracts in U.S. Physicians

NCT00000157 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2009-09-17

No results posted yet for this study

Summary

To determine whether 325 mg of aspirin taken on -alternate days reduces the risk of developing cataract among male U.S. physicians who were aged 40 to 84 in 1982.

To identify potential risk factors for cataract development, such as age, blood pressure, blood cholesterol, height, diabetes, medication use, and history of previous eye trauma or surgery.

Conditions

  • Cataract

Interventions

DRUG

Aspirin

Sponsors & Collaborators

  • National Eye Institute (NEI)

    lead NIH

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION

Eligibility

Min Age
40 Years
Max Age
84 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1982-04-30
Completion
1988-01-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000157 on ClinicalTrials.gov